These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 8832008

  • 1. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.
    Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Treleaven J.
    Bone Marrow Transplant; 1996 Jul; 18(1):151-6. PubMed ID: 8832008
    [Abstract] [Full Text] [Related]

  • 2. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Singhal S.
    Bone Marrow Transplant; 2002 May; 29(10):853-9. PubMed ID: 12058235
    [Abstract] [Full Text] [Related]

  • 3. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.
    Mehta J, Powles R, Horton C, Milan S, Singhal S, Treleaven J.
    Bone Marrow Transplant; 1995 Jun; 15(6):853-8. PubMed ID: 7581080
    [Abstract] [Full Text] [Related]

  • 4. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Jun; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 7. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
    Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringdén O, Barrett AJ, GVHD Working Committee of Center for International Blood and Marrow Transplant Research.
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T, Singhal S.
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [Abstract] [Full Text] [Related]

  • 9. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS, Kim CC, Lee MH, Lee JJ, Chung IJ, Kim HJ, Lee JW.
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S.
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.
    Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J.
    Bone Marrow Transplant; 1996 Dec; 18(6):1049-55. PubMed ID: 8971372
    [Abstract] [Full Text] [Related]

  • 13. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
    Rowley SD, Liang PS, Ulz L.
    Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
    [Abstract] [Full Text] [Related]

  • 14. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
    Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socié G, Golmard JL, Jouet JP, French Society of Bone Marrow Transplantation and Cell Therapy.
    J Clin Oncol; 2006 Dec 20; 24(36):5695-702. PubMed ID: 17116940
    [Abstract] [Full Text] [Related]

  • 16. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
    Lamparelli T, van Lint MT, Gualandi F, Raiola AM, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Bregante S, Berisso G, Dominietto A, Di Grazia C, Bruno B, Sessarego M, Casarino L, Verdiani S, Bacigalupo A.
    Bone Marrow Transplant; 2000 Dec 20; 26(12):1305-11. PubMed ID: 11223970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Are HLA antigens a risk factor for acute GVHD in thalassemic patients receiving HLA-identical stem cell transplantation?
    Mohyeddin Bonab M, Alimoghaddam K, Vatandoust S, Forouzia F, Jahani M, Ghavamzadeh A.
    Transplant Proc; 2004 Dec 20; 36(10):3190-3. PubMed ID: 15686726
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
    Hernández-Boluda JC, Marín P, Carreras E, Aguilar JL, Grañena A, Rozman C, Montserrat E.
    Haematologica; 1999 Jan 20; 84(1):26-31. PubMed ID: 10091390
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.